HCA Healthcare UK has opened two new cancer centres in central London to meet growing demand from private patients.
The US-owned company has invested £50m in the sites in Southwark and Chelsea, taking its total investment in cancer services to £100m since 2008.
Opened at the end of last month, the new £38.2m London Bridge Hospital, Private Care at Guy’s occupies the top four floors of the new cancer centre at
Guy’s Hospital in Southwark. Comprising 53 beds, the facility hosts the UK’s first integrated robotics theatre, including the Da Vinci robotic system,
and has a four-bed intensive care unit. The move is the latest expansion of HCA’s London Bridge campus, which opened a £30m outpatient and diagnostics
centre at The Shard last year. All cancer services at the existing London Bridge hospital will now transfer to the new site.
The second site is a £12m newly built outpatients and diagnostics centre in Sydney Street, Chelsea, which will offer a range of cancer treatments
provided by Leaders in Oncology Care (LOC). A blood laboratory and aseptic pharmacy manufacturing suite and a digital PET CT scanner have been installed
at the 30,000sqft site. Patients will also have access to inpatient and intensive care facilities at HCA’s nearby Lister Hospital.
HCA CEO Mike Neeb said: ‘At HCA Healthcare UK we’re committed to providing the very best in expert cancer treatments with our specialist network of
facilities in London, Manchester and around the UK, and we’re proud to continue and strengthen this legacy by opening two new facilities this week. We
know that patients and their families demand the best when it comes to cancer, and we aim to offer that reassurance; that their loved ones are getting
the very best care available, without delay.’
According to LaingBuisson consultant Ted Townsend, the investment confirms the growing trend for private hospitals in London to be able to treat higher
acuity patients, often with complex medical needs.
‘Oncology is sadly a growing medical specialty, and the services offered by HCA should appeal to both UK and overseas patients,’ he said.